Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis

World Journal of Gastroenterology

Volumn 18, Issue 32, 2012, Pages 4278-4287

  Pacheco, Rodrigo Goulart ^a   Esposito, Christiano Costa ^a   Müller, Lucas C M ^a   Castelo Branco, Morgana T L ^a   Quintella, Leonardo Pereira ^a   Chagas, Vera Lucia A ^a   de Souza, Heitor Siffert P ^a   Schanaider, Alberto ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Butyrate; Cytokines; Diversion colitis; Glutamine; Shortchain fatty acids

Indexed keywords

BUTYRIC ACID; COLLAGEN FIBER; ENEMA; GLUTAMINE; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COLITIS; COLON MUCOSA; COLONOSCOPY; COLOSTOMY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIVERSION COLITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GOBLET CELL; HYPEREMIA; INTESTINAL FIBROSIS; MALE; NONHUMAN; RAT; VIDEOENDOSCOPY;

EID: 84867719467     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i32.4278     Document Type: Article

References (50)

1. Glotzer DJ, Glick ME, Goldman H. Proctitis and colitis following diversion of the fecal stream. Gastroenterology 1981; 80: 438-441
2. Ma CK, Gottlieb C, Haas PA. Diversion colitis: a clinicopathologic study of 21 cases. Hum Pathol 1990; 21: 429-436
3. Ona FV, Boger JN. Rectal bleeding due to diversion colitis. Am J Gastroenterol 1985; 80: 40-41
4. Lusk LB, Reichen J, Levine JS. Aphthous ulceration in diversion colitis. Clinical implications. Gastroenterology 1984; 87: 1171-1173
5. Whelan RL, Abramson D, Kim DS, Hashmi HF. Diversion colitis. A prospective study. Surg Endosc 1994; 8: 19-24
6. Longatti TS, Acedo SC, de Oliveira CC, Miranda DD, Priolli DG, Ribeiro ML, Gambero A, Martinez CA. Inflammatory alterations in excluded colon in rats: a comparison with chemically induced colitis. Scand J Gastroenterol 2010; 45: 315-324
7. Castro LS, Schanaider A, Bettina WC. Colitis following fecal diversion: still a challenge. Acta Cir Bras 2000; 15: 3-6
8. Haas PA, Fox TA, Szilagy EJ. Endoscopic examination of the colon and rectum distal to a colostomy. Am J Gastroenterol 1990; 85: 850-854
9. Martinez CA, Nonose R, Spadari AP, Máximo FR, Priolli DG, Pereira JA, Margarido NF. Quantification by computerized morphometry of tissue levels of sulfomucins and sialomucins in diversion colitis in rats. Acta Cir Bras 2010; 25: 231-240
10. Geraghty JM, Talbot IC. Diversion colitis: histological features in the colon and rectum after defunctioning colostomy. Gut 1991; 32: 1020-1023
11. Neut C, Colombel JF, Guillemot F, Cortot A, Gower P, Quandalle P, Ribet M, Romond C, Paris JC. Impaired bacterial flora in human excluded colon. Gut 1989; 30: 1094-1098
12. Edwards CM, George B, Warren B. Diversion colitis--new light through old windows. Histopathology 1999; 34: 1-5
13. Martinez CA, Ribeiro ML, Gambero A, Miranda DD, Pereira JA, Nadal SR. The importance of oxygen free radicals in the etiopathogenesis of diversion colitis in rats. Acta Cir Bras 2010; 25: 387-395
14. Jørgensen JR, Clausen MR, Mortensen PB. Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes. Gut 1997; 40: 400-405
15. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009; 28: 88-93
16. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain JP. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 2010; 16: 684-695
17. Vanhoutvin SA, Troost FJ, Hamer HM, Lindsey PJ, Koek GH, Jonkers DM, Kodde A, Venema K, Brummer RJ. Butyrate-induced transcriptional changes in human colonic mucosa. PLoS One 2009; 4: e6759
18. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533
19. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521
20. Oliveira AJ, Pinto Júnior FE, Formiga MC, Melo SP, Brandao-Neto J, Ramos AM. Comparison of prophylactic and therapeutic use of short-chain fatty acid enemas in diversion colitis: a study in Wistar rats. Clinics (Sao Paulo) 2010; 65: 1351-1356
21. Scheppach W, Müller JG, Boxberger F, Dusel G, Richter F, Bartram HP, Christl SU, Dempfle CE, Kasper H. Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol 1997; 9: 163-168
22. Bloemen JG, Schreinemacher MH, de Bruine AP, Buurman WA, Bouvy ND, Dejong CH. Butyrate enemas improve intestinal anastomotic strength in a rat model. Dis Colon Rectum 2010; 53: 1069-1075
23. Wilmore DW, Shabert JK. Role of glutamine in immunologic responses. Nutrition 1998; 14: 618-626
24. Coëffier M, Marion-Letellier R, Déchelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 518-524
25. Feng D, Xu W, Chen G, Hang C, Gao H, Yin H. Influence of glutamine on intestinal inflammatory response, mucosa structure alterations and apoptosis following traumatic brain injury in rats. J Int Med Res 2007; 35: 644-656
26. Israeli E, Berenshtein E, Wengrower D, Aptekar L, Kohen R, Zajicek G, Goldin E. Prophylactic administration of topical glutamine enhances the capability of the rat colon to resist inflammatory damage. Dig Dis Sci 2004; 49: 1705-1712
27. Kaya E, Gür ES, Ozgüç H, Bayer A, Tokyay R. L-glutamine enemas attenuate mucosal injury in experimental colitis. Dis Colon Rectum 1999; 42: 1209-1215
28. San-Miguel B, Crespo I, Kretzmann NA, Mauriz JL, Marroni N, Tuñón MJ, González-Gallego J. Glutamine prevents fibrosis development in rats with colitis induced by 2,4,6-trinitrobenzene sulfonic acid. J Nutr 2010; 140: 1065-1071
29. Roda A, Simoni P, Magliulo M, Nanni P, Baraldini M, Roda G, Roda E. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007; 13: 1079-1084
30. Keli E, Bouchoucha M, Devroede G, Carnot F, Ohrant T, Cugnenc PH. Diversion-related experimental colitis in rats. Dis Colon Rectum 1997; 40: 222-228
31. Neut C, Guillemot F, Gower-Rousseau C, Biron N, Cortot A, Colombel JF. [Treatment of diversion colitis with shortchain fatty acids. Bacteriological study]. Gastroenterol Clin Biol 1995; 19: 871-875
32. Pinto-Jnior FEL, Oliveira AJF, Medeiros KF, Ramos AM, Ramos CC. Histopathological consequences of colostomy in the defunctional intestinal segment: an experimental study in rats. Col Bras Cir 1999; 26: 327-333
33. Deruyter L, Delvaux G, Willems G. Restoration of colorectal continuity reverses atrophy in human rectal mucosa. Dig Dis Sci 1990; 35: 488-494
34. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-243
35. Scheppach W, Christl SU, Bartram HP, Richter F, Kasper H. Effects of short-chain fatty acids on the inflamed colonic mucosa. Scand J Gastroenterol Suppl 1997; 222: 53-57
36. Ahmad MS, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, Murthy SN. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 2000; 46: 493-499
37. Velázquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol 1997; 427: 123-134
38. Galvez J, Rodríguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005; 49: 601-608
39. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 2010; 29: 738-744
40. Assisi RF. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008; 54: 231-238
41. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119
42. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320: 23-28
43. de Oliveira-Neto JP, de Aguilar-Nascimento JE. Intraluminal irrigation with fibers improves mucosal inflammation and atrophy in diversion colitis. Nutrition 2004; 20: 197-199
44. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991; 325: 928-937
45. Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-461
46. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009; 3: 77-97
47. Dignass AU, Stow JL, Babyatsky MW. Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta. Gut 1996; 38: 687-693
48. Kiliç ZM, Ayaz S, Ozin Y, Nadir I, Cakal B, Ulker A. Plasma transforming growth factor-beta1 level in inflammatory bowel disease. Turk J Gastroenterol 2009; 20: 165-170
49. Nancey S, Moussata D, Graber I, Claudel S, Saurin JC, Flourié B. Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: a link from inflammatory process to mucosal damage? Inflamm Bowel Dis 2005; 11: 559-566
50. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005; 280: 36099-36109